Abstract

The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin-binding affinity. In human plasma, AT circulates as a mixture of the α-form bearing four oligosaccharides and the β-form lacking an oligosaccharide at Asn135. However, it remains unclear how the immature high-mannose-type oligosaccharides produced by mammalian cells affect biological activities of AT. Here, we succeeded in directly comparing the activities between the high-mannose and complex types. Interestingly, although there were no substantial differences in thrombin inhibitory activity, the high-mannose type showed higher heparin-binding affinity. The anticoagulant activities were increased by heparin and correlated with the heparin-binding affinity, resulting in the strongest anticoagulant activity being displayed in the β-form with the high-mannose type. In pharmacokinetic profiling, the high-mannose type showed a much shorter plasma half-life than the complex type. The β-form was found to have a prolonged plasma half-life compared with the α-form for the high-mannose type; conversely, the α-form showed a longer half-life than the β-form for the complex-type. The present study highlights that AT physiological activities are strictly controlled not only by a core fucose at the reducing end but also by the high-mannose-type structures at the nonreducing end. The β-form with the immature high-mannose type appears to function as a more potent anticoagulant than the AT typically found in human plasma, once it emerges in the blood.

Highlights

  • Human antithrombin (AT) is a serine protease inhibitor consisting of 432 amino acids; it inactivates several enzymes of the coagulation system and is produced by the liver and vascular endothelial cells

  • The homogeneous α-forms of the two recombinant human AT (rhAT) bearing four oligosaccharides were separated from the β-form lacking an oligosaccharide at Asn135 by heparin-affinity chromatography, followed by anion-exchange and hydroxyapatite chromatography as described previously (Karlsson and Winge 2003; Mochizuki et al 2005)

  • The aggregates and latent forms were successfully removed by heparin-affinity and anionexchange chromatography, and they were present at

Read more

Summary

Introduction

Human antithrombin (AT) is a serine protease inhibitor consisting of 432 amino acids; it inactivates several enzymes of the coagulation system and is produced by the liver and vascular endothelial cells. The biological activity of the rhAT produced by transgenic goats is quite different from that of phAT due to its unusual oligosaccharide structures; it has a 4-fold higher heparin-binding affinity and much shorter serum halflife compared with those of phAT (Dickneite 2008). These observations show that the physiological activities of human AT are precisely controlled by its oligosaccharide structures, and illustrate the difficulty of generating an rhAT equivalent of phAT. The pharmacokinetics and physiological activities, including heparin binding, thrombin inhibition and anticoagulation, of these four rhATs in humans were compared in side-by-side experiments

Results
Discussion
Materials and methods
Conflict of interest statement
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call